BRAF and prostate carcinoma: To the best of our knowledge, this is the first reported case of the efficacy of this combination therapy in a patient with BRAF Class I alterations, which occur at the V600 codon and exhibit extremely strong kinase activity by stimulating monomeric activation of BRAF in prostate cancer (27).